Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16430998 | 0.90 | BCL3 (0.77) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL29849943 | 0.90 | BCL3 (0.77) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL17870592 | 0.88 | BCL3 (0.83) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL16430547 | 0.87 | BCL3 (0.74) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL29849602 | 0.87 | BCL3 (0.74) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL29849945 | 0.85 | BCL3 (1.00) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL16430708 | 0.85 | BCL3 (1.00) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL29849812 | 0.85 | ALDH1A1 (0.80) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL16431097 | 0.85 | ALDH1A1 (0.80) | BCL3ALDH1A1GAAPOLBHTT | |
| SCHEMBL16430973 | 0.83 | POLB (0.87) | BCL3ALDH1A1GAAPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027594-B1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-08-10 | — | — | EP | disclosed |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-01-20 | — | — | US | disclosed |
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-01-30 | — | — | US | disclosed |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | BCL3 1/4885ALDH1A1 1824/4885GAA 3319/4885 |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL3 1/4885ALDH1A1 1824/4885GAA 3319/4885 |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL3 1/4885ALDH1A1 2191/4885GAA 3438/4885 |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | BCL3 1/4885ALDH1A1 2191/4885GAA 3438/4885 |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | BCL3 1/4885ALDH1A1 2191/4885GAA 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.